Citations

Showing 10 of 108094 citations.

Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis
Ho, Matthew , Zanwar, Saurabh , Ailawadhi, Sikander , Larsen, Jeremy T. , Bergsagel, Leif, Binder, Moritz , Chanan‐Khan, Asher , Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Lacy, Martha Q. , Sher, Taimur , Warsame, Rahma , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Bergsagel, P. Leif , Bergsagel, P. Leif , Ailawadhi, Sikander , Larsen, Jeremy, Binder, Moritz , Dispenzieri, Angela , Gertz, Morie A , Gonsalves, Wilson , Kourelis, Taxiarchis , Leung, Nelson , Muchtar, E , Warsame, Rahma , Hwa, Yi L , Rajkumar, S Vincent , Kumar, Shaji K , Dingli, David , Ho, Matthew , Buadi, Francis K. , Dispenzieri, Angela , Fonseca, Rafaël , Gertz, Morie A. , Gonsalves, Wilson I. , Go, Ronald S. , Leung, Nelson , Lin, Yi , Muchtar, Eli , Roy, Vivek , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | October 13, 2022 | Volume: 98 | Issue: 1 | Pages: 49-55

10.1002/ajh.26762 | PMID 36226510 Get It

AbstractPatients with multiple myeloma (MM) have a lower efficacy from COVID‐19 vaccination and a high rate of mortality from COVID‐19 in hospitalized patients. However, the overall rate and severity of COVID‐19 infection in all settings (including non‐hospitalized patients) and the independent impact of plasma cell‐directed therapies on outcomes needs further study. We reviewed the medical records of 9225 patients with MM or AL amyloidosis (AL) seen at Mayo Clinic Rochester, Arizona, and Florida between 12/01/2019 and 8/31/2021 and identified 187 patients with a COVID‐19 infection (n = 174 MM, n = 13 AL). The infection rate in our cohort was relatively low at 2% but one‐fourth of the COVID‐19 infections were severe. Nineteen (10%) patients required intensive care unit (ICU) admission and 5 (3%) patients required mechanical ventilation. The mortality rate among hospitalized patients with COVID‐19 was 22% (16/72 patients). Among patients that were fully vaccinated at the time of infection (n = 12), two (17%) developed severe COVID‐19 infection, without any COVID‐related death. On multivariable analysis, treatment with CD38 antibody within 6 months of COVID‐19 infection [Risk ratio (RR) 3.6 (95% CI: 1.2, 10.5), p = .02], cardiac [RR 4.1 (95% CI: 1.3, 12.4), p = .014] or pulmonary comorbidities [RR 3.6 (95% CI 1.1, 11.6); p = .029] were independent predictors for ICU admission. Cardiac comorbidity [RR 2.6 (95% CI: 1.1, 6.5), p = .038] was an independent predictor of mortality whereas MM/AL in remission was associated with lower mortality [RR 0.4 (95% CI: 0.2–0.8); p = .008].
Quality, safety, and implementation science in acute kidney care
Rewa, Oleksa , Kashani, Kianoush

Mayo Clinic

Current Opinion in Critical Care | October 13, 2022 | Volume: 28 | Issue: 6 | Pages: 613-621

10.1097/mcc.0000000000000999 | PMID 36226720 Get It

Purpose of review Quality and safety are important themes in acute kidney care (AKC). There have been many recent initiatives highlighting these aspects. However, for these to become part of clinical practice, a rigorous implementation science methodology must be followed. This review will present these practices and will highlight recent initiatives in acute kidney injury (AKI), kidney replacement therapy (KRT) and recovery from AKI. Recent findings The 22nd Acute Disease Quality Initiative (ADQI) focused on achieving a framework for improving AKI care. This has led to various quality improvement (QI) initiatives that have been implemented following a robust implementation science methodology. In AKI, QI initiatives have been focused on implementing care bundles and early detection systems for patients at risk or with AKI. KRT initiatives have focused on measuring and reporting key performance indicators (KPIs), and providing targeted feedback and education to improve delivery of KRT. Finally, it has been recognized that post-AKI care is vitally important, and ongoing work has been focused on implementing pathways to ensure continuing kidney-focused care. Summary Quality and safety continue to be important focuses in AKC. Although recent work have focused on initiatives to improve these themes, additional work is necessary to further develop these items as we strive to improve the care to patients with AKI.
Giant molluscum contagiosum of the face with periorbital cellulitis
Johnson, Alexander Achille , Tran, Ann Q. , Tooley, Andrea A. , García, María, Kazim, Michael, Johnson, Alexander A , Garcia, Maria

Mayo Clinic

Orbit | October 13, 2022 | Volume: 45 | Issue: 1 | Pages: 247-247

10.1080/01676830.2022.2126500 | PMID 36226531 Get It

Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle
Dodick, David W. , Blumenfeld, Andrew , Singh, Rashmi B. Halker , Hsu, Cheng‐Pang, Peng, Cheng , Snellman, Josefin , Chehrenama, Mahan, Blumenfeld, Andrew M , Halker Singh, Rashmi B , Ailani, Jessica , Dodick, David W , Williams, Rachel , Zhang, Feng , Chen, Po‐Wei , Ailani, Jessica

Mayo Clinic

Headache: The Journal of Head and Face Pain | October 13, 2022 | Volume: 63 | Issue: 2 | Pages: 233-242

10.1111/head.14403 | PMID 36226464 Get It

Abstract Background Treatment wearing‐off has been reported for calcitonin gene‐related peptide‐pathway monoclonal antibodies, including erenumab, specifically in the last week of the monthly dosing cycle. Objective We sought to determine the consistency of erenumab effect throughout the monthly treatment cycle. Methods In this post hoc analysis of four pivotal double‐blind, randomized controlled studies of erenumab in episodic and chronic migraine, we assessed wearing‐off based on change in weekly migraine days at week 4 versus average over weeks 1–3 in each monthly dosing cycle. Analyses were conducted at each monthly dosing cycle in all patients, in responders (≥50% reduction in weekly migraine days), and in consistent responders (response in ≥2monthly cycles). Results There was no evidence of wearing‐off in the full study populations of two global studies (N = 946 and N = 656) and two Japan studies (N = 475 and N = 261). In the full study population, mean change in weekly migraine days at week 4 compared with the average over week 1–3 ranged from 0.15 days improvement to 0.19 days worsening in the placebo group and 0.08 days improvement to 0.20 days worsening in the erenumab groups. A subgroup of responders experienced wearing‐off, but the extent of wearing‐off did not differ between erenumab and placebo groups. The mean change in weekly migraine days at week 4 compared with the average over weeks 1–3 ranged from 0.34 to 0.61 days worsening in the placebo group and 0.27 to 0.78 days worsening in the erenumab groups. Few patients had persistent wearing‐off in ≥2 consecutive monthly treatment cycles. For erenumab‐treated responders, serum erenumab concentrations were similar among patients experiencing wearing‐off and those maintaining response. Conclusion No systematic wearing‐off with erenumab was identified. Further research is needed to determine if wearing‐off reported for some patients in clinical practice reflects a true treatment response pattern or normal fluctuations in migraine frequency.
Transformed Waldenström Macroglobulinemia: Update on Diagnosis, Prognosis and Treatment
Durot, Éric , Tomowiak, Cécile , Toussaint, Elise , Morel, Pierre , Talaulikar, Dipti , Kapoor, Prashant , Castillo, Jorge J. , Delmer, Alain , Talaulikar, Dipti , Tomowiak, Cécile , Castillo, Jorge J , Delmer, Alain Jacques , Durot, Eric

Mayo Clinic

Hemato | October 12, 2022 | Volume: 3 | Issue: 4 | Pages: 650-662

10.3390/hemato3040044 Get It

Histological transformation (HT) to an aggressive lymphoma results from a rare evolution of Waldenström macroglobulinemia (WM). A higher incidence of transformation events has been reported in MYD88 wild-type WM patients. HT in WM can be histologically heterogeneous, although the diffuse large B-cell lymphoma of activated B-cell subtype is the predominant pathologic entity. The pathophysiology of HT is largely unknown. The clinical suspicion of HT is based on physical deterioration and the rapid enlargement of the lymph nodes in WM patients. Most transformed WM patients present with elevated serum lactate dehydrogenase (LDH) and extranodal disease. A histologic confirmation regarding the transformation to a higher-grade lymphoma is mandatory for the diagnosis of HT, and the choice of the biopsy site may be dictated by the findings of the 18fluorodeoxyglucose-positron emission tomography/computed tomography. The prognosis of HT in WM is unfavorable, with a significantly inferior outcome compared to WM patients without HT. A validated prognostic score based on 3 adverse risk factors (elevated LDH, platelet count < 100 × 109/L and any previous treatment for WM) stratifies patients into 3 risk groups. The most common initial treatment used is a chemo-immunotherapy (CIT), such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). The response duration is short and central nervous system relapses are frequent. Whether autologous stem cell transplantation could benefit fit patients responding to CIT remains to be studied.
Pim-1 kinase is a positive feedback regulator of the senescent lung fibroblast inflammatory secretome
Gao, Ashley Y. , Espinosa, Ana Maria Diaz, Gianì, Fiorenza , Pham, Tho X., Aravamudhan, Aja, Bartman, Colleen M. , Ligresti, Giovanni , Caporarello, Nunzia , Schafer, Marissa , Haak, Andrew J. , Espinosa, Ana M. Diaz , Diaz Espinosa, Ana M , Carver, Chase M., Bartman, Colleen M , Caporarello, Nunzia , Schafer, Marissa J , Haak, Andrew J , Carver, Chase Matthew

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | October 12, 2022 | Volume: 323 | Issue: 6 | Pages: L685-L697

10.1152/ajplung.00023.2022 | PMID 36223640 Get It

Cellular senescence is emerging as a driver of idiopathic pulmonary fibrosis (IPF), a progressive and fatal disease with limited effective therapies. The senescence-associated secretory phenotype (SASP), involving the release of inflammatory cytokines and profibrotic growth factors by senescent cells, is thought to be a product of multiple cell types in IPF, including lung fibroblasts. NF-κB is a master regulator of the SASP, and its activity depends on the phosphorylation of p65/RelA. The purpose of this study was to assess the role of Pim-1 kinase as a driver of NF-κB-induced production of inflammatory cytokines from low-passage IPF fibroblast cultures displaying markers of senescence. Our results demonstrate that Pim-1 kinase phosphorylates p65/RelA, activating NF-κB activity and enhancing IL-6 production, which in turn amplifies the expression of PIM1, generating a positive feedback loop. In addition, targeting Pim-1 kinase with a small molecule inhibitor dramatically inhibited the expression of a broad array of cytokines and chemokines in IPF-derived fibroblasts. Furthermore, we provide evidence that Pim-1 overexpression in low-passage human lung fibroblasts is sufficient to drive premature senescence, in vitro. These findings highlight the therapeutic potential of targeting Pim-1 kinase to reprogram the secretome of senescent fibroblasts and halt IPF progression.
Oil Red O Staining of Pulmonary Macrophages in Bronchoalveolar Lavage Specimens Is Not Specific for Vaping-Associated Lung Injury
Thangaiah, Judith Jebastin, Booth, Christine N. , Brainard, Jennifer , Elsheikh, Tarik M. , Ondrejka, Sarah L. , Thilagar, Bright , Mukhopadhyay, Sanjay , Jebastin, Judith A S , Ondrejka, Sarah , Thilagar, Bright P. , Mukhopadhyay, Sanjay , Reynolds, Jordan , Doxtader, Erika

Mayo Clinic

American Journal of Clinical Pathology | October 12, 2022 | Volume: 158 | Issue: 6 | Pages: 723-729

10.1093/ajcp/aqac118 | PMID 36222561 Get It

Abstract Objectives Oil Red O (ORO) positivity in bronchoalveolar lavage (BAL) fluid macrophages in the setting of e-cigarette, or vaping, product use–associated acute lung injury (EVALI) has been frequently requested by clinicians based on rare reports and subsequent US Centers for Disease Control and Prevention guidelines. The aim of this study was to determine the specificity of ORO staining in BAL specimens with disease states other than EVALI. Methods Consecutive BAL specimens (October-December 2019) were stained with ORO. The lipid-laden macrophage index (LLMI) was calculated for each case. Results We studied BAL samples from 50 patients. Indications for BAL were surveillance bronchoscopy for lung transplantation (27/50), suspected infection (12/50), sarcoidosis/suspected sarcoidosis (3/50), nodules or ground-glass opacities (3/50), hemoptysis (2/50), asthma or eosinophilic pneumonia (2/50), and idiopathic pulmonary fibrosis (1/50). ORO staining was seen in BAL fluid macrophages in 45 of 50 cases (focal in 18, moderate in 23, diffuse in 4); LLMI ranged from 0 to 218. Using a threshold of LLMI of 85 or higher as positive, ORO was positive in 7 of 50 (14%) cases (range, 85-218). Conclusions ORO staining in BAL fluid macrophages is not specific for EVALI. Even when an LLMI of 85 or higher is used as a threshold for positivity, ORO positivity occurs in a significant subset of non–vaping-related cases.
CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission
Kharfan‐Dabaja, Mohamed A. , Salmenniemi, Urpu , Mielke, Stephan , Chevallier, Patrice , Rubio, Marie Thérèse, Balsat, Marie , Pioltelli, Pietro, Ménard, Anne‐Lise, Huynh, Anne , Schaap, Nicolaas , Rodríguez, Arancha Bermúdez, Cornelissen, Jan J. , Yakoub‐Agha, Ibrahim , Aljurf, Mahmoud, Giebel, Sebastian, Brissot, Éolia , Peric, Zina, Nagler, Arnon, Mohty, Mohamad , Perić, Zinaida , Rubio, Marie‐Thérèse , Yakoub-Agha, Ibrahim , Mielke, Stephan , Mohty, Mohamad , Labopin, Myriam , Bazarbachi, Ali , Socié, Gèrard , Aljurf, Mahmoud , Giebel, Sebastian , Nagler, Arnon

Mayo Clinic

HemaSphere | October 12, 2022 | Volume: 6 | Issue: 11 | Pages: e788

10.1097/hs9.0000000000000788 | PMID 36258923 Get It

Outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) for adult acute lymphoblastic leukemia (ALL) have improved over time. Studies have shown that total body irradiation (TBI) is the preferable type of myeloablative conditioning (MAC). However, outcomes based on central nervous system (CNS) involvement, namely CNS-positive versus CNS-negative, have not been compared. Here, we evaluated outcomes of 547 patients (CNS-positive = 96, CNS-negative = 451) who were allografted in the first complete remission (CR1) between 2009 and 2019. Primary endpoint was leukemia-free survival (LFS). Median follow-up was not different between the CNS-positive and CNS-negative groups (79 versus 67.2 months, P = 0.58). The CNS-positive group were younger (median age 31.3 versus 39.7 years, P = 0.004) and were allografted more recently (median year 2012 versus 2010, P = 0.003). In both groups, MAC was the preferred approach (82.3% versus 85.6%, P = 0.41). On multivariate analysis, the CNS-positive group had higher incidence of relapse (RI) (hazard ratio [HR] = 1.58 [95% confidence interval (CI) = 1.06-2.35], P = 0.025), but no adverse effect on LFS (HR = 1.38 [95% CI = 0.99-1.92], P = 0.057) or overall survival (OS) (HR = 1.28 [95% CI = 0.89-1.85], P = 0.18). A subgroup multivariate analysis limited to CNS-positive patients showed that a TBI-based MAC regimen resulted in better LFS (HR = 0.43 [95% CI = 0.22-0.83], P = 0.01) and OS (HR = 0.44 [95% CI = 0.21-0.92], P = 0.03) and lower RI (HR = 0.35 [95% CI = 0.15-0.79], P = 0.01). Another subgroup analysis in CNS-negative patients showed that MAC-TBI preparative regimens also showed a lower RI without a benefit in LFS or OS. While a MAC-TBI allo-HCT regimen may not be suitable to all, particularly for older patients with comorbidities, this approach should be considered for patients who are deemed fit and able to tolerate.
Impact of Active and Historical Cancers on the Management and Outcomes of Acute Myocardial Infarction Complicating Cardiogenic Shock
Patlolla, Sri Harsha , Bhat, Anusha Ganapati , Sundaragiri, Pranathi R., Cheungpasitporn, Wisit , Malleshappa, Sudeep K Siddappa , Pasupula, Deepak Kumar , Jaber, Wissam , Nicholson, William J. , Vallabhajosyula, Saraschandra , Cheungpasitporn, Wisit , Vallabhajosyula, Saraschandra , Harsha Patlolla, Sri , Doshi, Rajkumar

Mayo Clinic

Texas Heart Institute Journal | October 12, 2022 | Volume: 49 | Issue: 5 | Pages: No page available

10.14503/thij-21-7598 | PMID 36223249 Get It

Background There are limited data on the outcomes of acute myocardial infarction–cardiogenic shock (AMI-CS) in patients with concomitant cancer. Methods A retrospective cohort of adult AMI-CS admissions was identified from the National Inpatient Sample (2000–2017) and stratified by active cancer, historical cancer, and no cancer. Outcomes of interest included in-hospital mortality, use of coronary angiography, use of percutaneous coronary intervention, do-not-resuscitate status, palliative care use, hospitalization costs, and hospital length of stay. Results Of the 557,974 AMI-CS admissions during this 18-year period, active and historical cancers were noted in 14,826 (2.6%) and 27,073 (4.8%), respectively. From 2000 to 2017, there was a decline in active cancers (adjusted odds ratio, 0.70 [95% CI, 0.63–0.79]; P < .001) and an increase in historical cancer (adjusted odds ratio, 2.06 [95% CI, 1.89–2.25]; P < .001). Compared with patients with no cancer, patients with active and historical cancer received less-frequent coronary angiography (57%, 67%, and 70%, respectively) and percutaneous coronary intervention (40%, 47%, and 49%%, respectively) and had higher do-not-resuscitate status (13%, 15%, 7%%, respectively) and palliative care use (12%, 10%, 6%%, respectively) (P < .001). Compared with those without cancer, higher in-hospital mortality was found in admissions with active cancer (45.9% vs 37.0%; adjusted odds ratio, 1.29 [95% CI, 1.24–1.34]; P < .001) but not historical cancer (40.1% vs 37.0%; adjusted odds ratio, 1.01 [95% CI, 0.98–1.04]; P = .39). AMI-CS admissions with cancer had a shorter hospitalization duration and lower costs (all P < .001). Conclusion Concomitant cancer was associated with less use of guideline-directed procedures. Active, but not historical, cancer was associated with higher mortality in patients with AMI-CS.